Further validation with glioma patient public datasets was performed confirming that an increase of MT1-MMP expression at the mRNA level in GBM is observed compared to LGGs as oligodendroglioma and astrocytoma (grade II and III) (S1A and S1B Fig) and that high levels of MT1-MMP are associated with worse prognosis and a decreased survival in GBM patients (S1C Fig). This evidence concerns the gene MMP14 and astrocytoma (excluding glioblastoma).